506820 Stock Overview
AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
AstraZeneca Pharma India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹5,258.30 |
| 52 Week High | ₹7,208.00 |
| 52 Week Low | ₹3,131.10 |
| Beta | 0.38 |
| 1 Month Change | -2.34% |
| 3 Month Change | -8.03% |
| 1 Year Change | 59.33% |
| 3 Year Change | 36.93% |
| 5 Year Change | 124.43% |
| Change since IPO | 8,966.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 506820 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.1% | -3.4% | -3.7% |
| 1Y | 59.3% | 53.6% | 38.4% |
Return vs Industry: 506820 exceeded the Indian Pharmaceuticals industry which returned 53.6% over the past year.
Return vs Market: 506820 exceeded the Indian Market which returned 38.4% over the past year.
Price Volatility
| 506820 volatility | |
|---|---|
| 506820 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 506820's share price has been volatile over the past 3 months.
Volatility Over Time: 506820's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 947 | Sanjeev Panchal | www.astrazeneca.in |
AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brand names; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brand names. The company also offers products in the areas of renal, metabolic, and immunology diseases.
AstraZeneca Pharma India Limited Fundamentals Summary
| 506820 fundamental statistics | |
|---|---|
| Market cap | ₹131.46b |
| Earnings (TTM) | ₹1.39b |
| Revenue (TTM) | ₹11.97b |
94.4x
P/E Ratio11.0x
P/S RatioIs 506820 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506820 income statement (TTM) | |
|---|---|
| Revenue | ₹11.97b |
| Cost of Revenue | ₹4.86b |
| Gross Profit | ₹7.11b |
| Other Expenses | ₹5.72b |
| Earnings | ₹1.39b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 55.72 |
| Gross Margin | 59.43% |
| Net Profit Margin | 11.64% |
| Debt/Equity Ratio | 0.8% |
How did 506820 perform over the long term?
See historical performance and comparison